Is preclinical autoimmunity benign?: The case of cardiovascular disease

Rheumatic Disease Clinics of North America

Volumn 40, Issue 4, 2014, Pages 659-668

  Majka, Darcy S ^a   Chang, Rowland W ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Autoantibodies; Autoimmunity; Cardiovascular disease; Coronary artery calcification; Intima media thickness; Preclinical

Indexed keywords

ANTINUCLEAR ANTIBODY; BETA2 GLYCOPROTEIN 1 ANTIBODY; CARDIOLIPIN ANTIBODY; CYCLIC CITRULLINATED PEPTIDE ANTIBODY; DOUBLE STRANDED DNA ANTIBODY; LUPUS ANTICOAGULANT; PHOSPHOLIPID ANTIBODY; RHEUMATOID FACTOR; AUTOANTIBODY; CYCLIC CITRULLINATED PEPTIDE; CYCLOPEPTIDE;

ARTERIAL WALL THICKNESS; ATHEROGENESIS; AUTOIMMUNE DISEASE; AUTOIMMUNITY; B LYMPHOCYTE; CARDIOVASCULAR DISEASE; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY CALCIFICATION; CORONARY ARTERY DISEASE; CYTOKINE PRODUCTION; HEART INFARCTION; HUMAN; ISCHEMIC HEART DISEASE; NONHUMAN; REVIEW; RHEUMATIC DISEASE; RHEUMATOID ARTHRITIS; SYSTEMIC LUPUS ERYTHEMATOSUS; ASYMPTOMATIC DISEASE; ATHEROSCLEROSIS; BLOOD VESSEL CALCIFICATION; CAROTID ARTERY DISEASE; ECHOGRAPHY; IMMUNOLOGY;

ANTIBODIES, ANTINUCLEAR; ANTIBODIES, ANTIPHOSPHOLIPID; ARTHRITIS, RHEUMATOID; ASYMPTOMATIC DISEASES; ATHEROSCLEROSIS; AUTOANTIBODIES; AUTOIMMUNE DISEASES; AUTOIMMUNITY; CARDIOVASCULAR DISEASES; CAROTID ARTERY DISEASES; CAROTID INTIMA-MEDIA THICKNESS; CORONARY ARTERY DISEASE; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; PEPTIDES, CYCLIC; RHEUMATOID FACTOR; VASCULAR CALCIFICATION;

EID: 84908068147     PISSN: 0889857X     EISSN: 15583163     Source Type: Journal    
DOI: 10.1016/j.rdc.2014.07.006     Document Type: Review

References (63)

1. Arbuckle M.R., James J.A., Kohlhase K.F., et al. Development of anti-dsDNA autoantibodies prior to clinical diagnosis of systemic lupus erythematosus. Scand J Immunol 2001, 54(1-2):211-219.
2. Arbuckle M.R., McClain M.T., Rubertone M.V., et al. Development of autoantibodies before the clinical onset of systemic lupus erythematosus. NEngl J Med 2003, 349(16):1526-1533.
3. Arslan S., Erkut B., Ates A., et al. Pseudoaneurysm of left ventricular following left ventricular apical venting. Clin Res Cardiol 2009, 98(4):280-282.
4. Majka D.S., Deane K.D., Parrish L.A., et al. Duration of preclinical rheumatoid arthritis-related autoantibody positivity increases in subjects with older age at time of disease diagnosis. Ann Rheum Dis 2008, 67(6):801-807.
5. Majka D.S., Holers V.M. Can we accurately predict the development of rheumatoid arthritis in the preclinical phase?. Arthritis Rheum 2003, 48(10):2701-2705.
6. Rantapaa-Dahlqvist S., de Jong B.A., Berglin E., et al. Antibodies against cyclic citrullinated peptide and IgA rheumatoid factor predict the development of rheumatoid arthritis. Arthritis Rheum 2003, 48(10):2741-2749.
7. Eriksson C., Kokkonen H., Johansson M., et al. Autoantibodies predate the onset of systemic lupus erythematosus in northern Sweden. Arthritis Res Ther 2011, 13(1):R30.
8. Gerli R., Monti D., Bistoni O., et al. Chemokines, sTNF-Rs and sCD30 serum levels in healthy aged people and centenarians. Mech Ageing Dev 2000, 121(1-3):37-46.
9. Kim S.K., Bae J., Lee H., et al. Greater prevalence of seropositivity for anti-cyclic citrullinated peptide antibody in unaffected first-degree relatives in multicase rheumatoid arthritis-affected families. Korean J Intern Med 2013, 28(1):45-53.
10. Satoh M., Chan E.K., Ho L.A., et al. Prevalence and sociodemographic correlates of antinuclear antibodies in the United States. Arthritis Rheum 2012, 64(7):2319-2327.
11. van Schaardenburg D., Lagaay A.M., Otten H.G., et al. The relation between class-specific serum rheumatoid factors and age in the general population. Br J Rheumatol 1993, 32(7):546-549.
12. Arlestig L., Mullazehi M., Kokkonen H., et al. Antibodies against cyclic citrullinated peptides of IgG, IgA and IgM isotype and rheumatoid factor of IgM and IgA isotype are increased in unaffected members of multicase rheumatoid arthritis families from northern Sweden. Ann Rheum Dis 2012, 71(6):825-829.
13. Ramos P.S., Kelly J.A., Gray-McGuire C., et al. Familial aggregation and linkage analysis of autoantibody traits in pedigrees multiplex for systemic lupus erythematosus. Genes Immun 2006, 7(5):417-432.
14. Anolik J.H. Bcell biology and dysfunction in SLE. Bull NYU Hosp Jt Dis 2007, 65(3):182-186.
15. Townsend M.J., Monroe J.G., Chan A.C. B-cell targeted therapies in human autoimmune diseases: an updated perspective. Immunol Rev 2010, 237(1):264-283.
16. Canete J.D., Celis R., Moll C., et al. Clinical significance of synovial lymphoid neogenesis and its reversal after anti-tumour necrosis factor alpha therapy in rheumatoid arthritis. Ann Rheum Dis 2009, 68(5):751-756.
17. Weyand C.M., Goronzy J.J. Ectopic germinal center formation in rheumatoid synovitis. Ann N Y Acad Sci 2003, 987:140-149.
18. Avina-Zubieta J.A., Thomas J., Sadatsafavi M., et al. Risk of incident cardiovascular events in patients with rheumatoid arthritis: a meta-analysis of observational studies. Ann Rheum Dis 2012, 71(9):1524-1529.
19. Barbhaiya M., Solomon D.H. Rheumatoid arthritis and cardiovascular disease: an update on treatment issues. Curr Opin Rheumatol 2013, 25(3):317-324.
20. van Breukelen-van der Stoep D.F., Klop B., van Zeben D., et al. Cardiovascular risk in rheumatoid arthritis: how to lower the risk?. Atherosclerosis 2013, 231(1):163-172.
21. Ajeganova S., Andersson M.L., Frostegard J., et al. Disease factors in early rheumatoid arthritis are associated with differential risks for cardiovascular events and mortality depending on age at onset: a 10-year observational cohort study. JRheumatol 2013, 40(12):1958-1966.
22. Goodson N.J., Wiles N.J., Lunt M., et al. Mortality in early inflammatory polyarthritis: cardiovascular mortality is increased in seropositive patients. Arthritis Rheum 2002, 46(8):2010-2019.
23. Lopez-Longo F.J., Oliver-Minarro D., de la Torre I., et al. Association between anti-cyclic citrullinated peptide antibodies and ischemic heart disease in patients with rheumatoid arthritis. Arthritis Rheum 2009, 61(4):419-424.
24. Kramer H.R., Giles J.T. Cardiovascular disease risk in rheumatoid arthritis: progress, debate, and opportunity. Arthritis Care Res (Hoboken) 2011, 63(4):484-499.
25. El-Barbary A.M., Kassem E.M., El-Sergany M.A., et al. Association of anti-modified citrullinated vimentin with subclinical atherosclerosis in early rheumatoid arthritis compared with anti-cyclic citrullinated peptide. JRheumatol 2011, 38(5):828-834.
26. Gerli R., Sherer Y., Bocci E.B., et al. Precocious atherosclerosis in rheumatoid arthritis: role of traditional and disease-related cardiovascular risk factors. Ann N Y Acad Sci 2007, 1108:372-381.
27. Yurkovich M., Vostretsova K., Chen W., et al. Overall and cause-specific mortality in patients with systemic lupus erythematosus: a meta-analysis of observational studies. Arthritis Care Res (Hoboken) 2014, 66(4):608-616.
28. Petri M. The lupus anticoagulant is a risk factor for myocardial infarction (but not atherosclerosis): Hopkins Lupus Cohort. Thromb Res 2004, 114(5-6):593-595.
29. Gustafsson J., Gunnarsson I., Borjesson O., et al. Predictors of the first cardiovascular event in patients with systemic lupus erythematosus-a prospective cohort study. Arthritis Res Ther 2009, 11(6):R186.
30. Gustafsson J.T., Simard J.F., Gunnarsson I., et al. Risk factors for cardiovascular mortality in patients with systemic lupus erythematosus, a prospective cohort study. Arthritis Res Ther 2012, 14(2):R46.
31. Plazak W., Gryga K., Milewski M., et al. Association of heart structure and function abnormalities with laboratory findings in patients with systemic lupus erythematosus. Lupus 2011, 20(9):936-944.
32. Plazak W., Pasowicz M., Kostkiewicz M., et al. Influence of chronic inflammation and autoimmunity on coronary calcifications and myocardial perfusion defects in systemic lupus erythematosus patients. Inflamm Res 2011, 60(10):973-980.
33. Romero-Diaz J., Vargas-Vorackova F., Kimura-Hayama E., et al. Systemic lupus erythematosus risk factors for coronary artery calcifications. Rheumatology (Oxford) 2012, 51(1):110-119.
34. Edwards C.J., Syddall H., Goswami R., et al. The autoantibody rheumatoid factor may be an independent risk factor for ischaemic heart disease in men. Heart 2007, 93(10):1263-1267.
35. Liang K.P., Kremers H.M., Crowson C.S., et al. Autoantibodies and the risk of cardiovascular events. JRheumatol 2009, 36(11):2462-2469.
36. Tomasson G., Aspelund T., Jonsson T., et al. Effect of rheumatoid factor on mortality and coronary heart disease. Ann Rheum Dis 2010, 69(9):1649-1654.
37. Cambridge G., Acharya J., Cooper J.A., et al. Antibodies to citrullinated peptides and risk of coronary heart disease. Atherosclerosis 2013, 228(1):243-246.
38. Majka D.S., Chang R.W., Pope R.M., et al. Autoantibodies are associated with subclinical atherosclerosis and cardiovascular endpoints in Caucasian and African American women in a prospective study: the Multi-Ethnic Study of Atherosclerosis (MESA). Arthritis Rheum 2012, 64(10):S711. [abstract].
39. Grainger D.J., Bethell H.W. High titres of serum antinuclear antibodies, mostly directed against nucleolar antigens, are associated with the presence of coronary atherosclerosis. Ann Rheum Dis 2002, 61(2):110-114.
40. Adler Y., Finkelstein Y., Zandeman-Goddard G., et al. The presence of antiphospholipid antibodies in acute myocardial infarction. Lupus 1995, 4(4):309-313.
41. Brey R.L., Abbott R.D., Curb J.D., et al. Beta(2)-Glycoprotein 1-dependent anticardiolipin antibodies and risk of ischemic stroke and myocardial infarction: the Honolulu heart program. Stroke 2001, 32(8):1701-1706.
42. Dropinski J., Szczeklik W., Rubis P., et al. Anti-phospholipid antibodies and carotid-artery intima-media thickness in young survivors of myocardial infarction. Med Sci Monit 2003, 9(4):BR105-BR109.
43. Hughes J.R., Davies J.A. Anticardiolipin antibodies in clinical conditions associated with a risk of thrombotic events. Thromb Res 1998, 89(3):101-106.
44. Meroni P.L., Peyvandi F., Foco L., et al. Anti-beta 2 glycoprotein I antibodies and the risk of myocardial infarction in young premenopausal women. JThromb Haemost 2007, 5(12):2421-2428.
45. Sherer Y., Tenenbaum A., Praprotnik S., et al. Coronary artery disease but not coronary calcification is associated with elevated levels of cardiolipin, beta-2-glycoprotein-I, and oxidized LDL antibodies. Cardiology 2001, 95(1):20-24.
46. Veres K., Lakos G., Kerenyi A., et al. Antiphospholipid antibodies in acute coronary syndrome. Lupus 2004, 13(6):423-427.
47. Zuckerman E., Toubi E., Shiran A., et al. Anticardiolipin antibodies and acute myocardial infarction in non-systemic lupus erythematosus patients: a controlled prospective study. Am J Med 1996, 101(4):381-386.
48. George J., Harats D., Gilburd B., et al. Immunolocalization of beta2-glycoprotein I (apolipoprotein H) to human atherosclerotic plaques: potential implications for lesion progression. Circulation 1999, 99(17):2227-2230.
49. Doria A., Sherer Y., Meroni P.L., et al. Inflammation and accelerated atherosclerosis: basic mechanisms. Rheum Dis Clin North Am 2005, 31(2):355-362. viii.
50. Ames P.R., Margarita A., Delgado Alves J., et al. Anticardiolipin antibody titre and plasma homocysteine level independently predict intima media thickness of carotid arteries in subjects with idiopathic antiphospholipid antibodies. Lupus 2002, 11(4):208-214.
51. Margarita A., Batuca J., Scenna G., et al. Subclinical atherosclerosis in primary antiphospholipid syndrome. Ann N Y Acad Sci 2007, 1108:475-480.
52. Asanuma Y., Oeser A., Shintani A.K., et al. Premature coronary-artery atherosclerosis in systemic lupus erythematosus. NEngl J Med 2003, 349(25):2407-2415.
53. Majka D.S., Liu K., Pope R.M., et al. Antiphospholipid antibodies and sub-clinical atherosclerosis in the Coronary Artery Risk Development in Young Adults (CARDIA) cohort. Inflamm Res 2013, 62(10):919-927.
54. Maradit-Kremers H., Crowson C.S., Nicola P.J., et al. Increased unrecognized coronary heart disease and sudden deaths in rheumatoid arthritis: a population-based cohort study. Arthritis Rheum 2005, 52(2):402-411.
55. Sokolove J., Brennan M.J., Sharpe O., et al. Brief report: citrullination within the atherosclerotic plaque: a potential target for the anti-citrullinated protein antibody response in rheumatoid arthritis. Arthritis Rheum 2013, 65(7):1719-1724.
56. Kobayashi K., Lopez L.R., Matsuura E. Atherogenic antiphospholipid antibodies in antiphospholipid syndrome. Ann N Y Acad Sci 2007, 1108:489-496.
57. Hasunuma Y., Matsuura E., Makita Z., et al. Involvement of beta 2-glycoprotein I and anticardiolipin antibodies in oxidatively modified low-density lipoprotein uptake by macrophages. Clin Exp Immunol 1997, 107(3):569-573.
58. George J., Harats D., Gilburd B., et al. Adoptive transfer of beta(2)-glycoprotein I-reactive lymphocytes enhances early atherosclerosis in LDL receptor-deficient mice. Circulation 2000, 102(15):1822-1827.
59. George J., Afek A., Gilburd B., et al. Induction of early atherosclerosis in LDL-receptor-deficient mice immunized with beta2-glycoprotein I. Circulation 1998, 98(11):1108-1115.
60. Peters M.J., Symmons D.P., McCarey D., et al. EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis. Ann Rheum Dis 2010, 69(2):325-331.
61. Desai S.S., Myles J.D., Kaplan M.J. Suboptimal cardiovascular risk factor identification and management in patients with rheumatoid arthritis: a cohort analysis. Arthritis Res Ther 2012, 14(6):R270.
62. Toms T.E., Panoulas V.F., Douglas K.M., et al. Statin use in rheumatoid arthritis in relation to actual cardiovascular risk: evidence for substantial undertreatment of lipid-associated cardiovascular risk?. Ann Rheum Dis 2010, 69(4):683-688.
63. Iaccarino L., Bettio S., Zen M., et al. Premature coronary heart disease in SLE: can we prevent progression?. Lupus 2013, 22(12):1232-1242.